Major adverse cardiovascular events by baseline frailty
REGRESSION, REGRESSIONS
The primary trial outcome was rerun in the 9942 participants who had an FI available at baseline. Among those who were not frail 9.6% experienced a MACE outcome, while for those who were prefrail and frail, 15.8% and 27.4% experienced MACE, respectively. In the overall trial, the published HR (95% CI) compared with placebo for the 50‐, 150‐, and 300‐mg groups were 0.93 (0.80–1.07), 0.85 (0.74–0.98), and 0.86 (0.75–0.99); and for all doses versus placebo, it was 0.88 (0.79–0.97) (Ridker et al., Effect of canakinumab versus placebo on incident MACE, stratified by frailty.
Likelihood ratio test for trend from proportional hazard regression stratified by trial part.Rates are per 100 person years.Hazard ratio and confidence intervals from proportional hazard regressions stratified by trial part.